By Maxx Chatsko Gene therapy and gene editing get all the glory, but investors shouldn’t overlook an emerging group of tools. Few drug developers are more ambitious than Sarepta Therapeutics (SRPT) – Get Sarepta Therapeutics Inc. Report. The company boasts 34 pipeline programs spread across gene therapy, gene editing, and tools based on RNA. Although the company is primarily focused on muscle disorders such as Duchenne muscular dystrophy (DMD), it has recently branched out into diseases impacted by genes in the liver and brain. If its three approved drug products continue to ramp revenue, then…